Ng George K 4

What Happened
George K. Ng, CEO of Processa Pharmaceuticals (PCSA), reported a purchase of 1,843 shares on 2026-04-15 at $2.97 per share, for a total acquisition of $5,474. The filing lists the transaction code P (purchase) and describes it as an open-market or private purchase. Purchases are generally considered a more informative signal than sales, though the dollar amount here is modest.

Key Details

• Transaction date and price: 2026-04-15 — 1,843 shares at $2.97 each (total $5,474).
• Transaction type: Code P (Purchase); described as open-market or private purchase.
• Filing date: 2026-04-17 (filed two days after the transaction) — appears to be filed within the typical two-business-day Form 4 window.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes/other: No 10b5‑1 plan, tax withholding, option exercise, or award footnotes noted in the provided details.

Context
This is a direct share purchase by the CEO, which can indicate confidence, but the small dollar amount ($~5.5k) represents a modest personal investment and may be routine. No derivative transactions, sales, or grants are involved in this filing.